Japan, 1, 2 it is important to assess the risk of AdV-HC and to make a rapid diagnosis of HC for early intervention.
Sixty-nine patients who underwent the first allogeneic HSCT between April 2005 and December 2006 were enrolled before the start of preparative conditioning. Standard urinalysis was performed at least once a week from 2 weeks before HSCT up to 3 months post HSCT and at the outpatient clinic every 2 or 4 weeks thereafter until 1 year post HSCT. In this study, late-onset HC was defined as HC that occurred 10 days after completion of the preparative In the Kaplan-Meyer curves, death without incidence of HC was defined as a competing event. The cumulative incidence of late-onset HC (solid line) over intervals from the start of allogeneic HSCT to the first day of hematuria was 23%, with a median interval after HSCT of 53 days (range: 24-139 days). The cumulative incidence of AdV-HC (dashed line) was 11%, with a median interval after HSCT of 53 days (range: 24-78 days). (b) Comparison of urinary and serum AdV loads among patients with HC from whom AdV was isolated by viral culture (AdV-HC), patients with HC from whom AdV was not isolated by viral culture (non-AdV-HC), and patients without HC (no HC). (c) Comparison of urinary and serum BKV loads among AdV-HC, non-AdV-HC and no HC group. The detection limit of the assay for both serum and urine was 1.0 Â 10 2 copies/mL. To determine the significance of differences between two independent groups, the Mann-Whitney U-test was used. treatment. According to the published criteria, 3 we recorded grade 2 or higher HC as a clinically important complication in HSCT patients and performed viral cultures of their urine. As Akiyama et al. 2 reported that the viral culture is equivalent to PCR for diagnosis of AdV-HC, we classified HC into AdV-HC and nonAdV-HC based on the culture results. Among 69 subjects, 15 patients developed late-onset HC during the 1-year follow-up period (Figure 1a ). Twenty-eight (40.6%) of 69 patients developed moderate or severe acute GVHD. Thirty-six patients (52.2%) were treated with corticosteroids for post-transplant complications such as engraftment syndrome and acute GVHD. The occurrence of acute GVHD was strongly associated with the incidence of HC according to the w 2 -test (Po0.001). Patients treated with corticosteroids developed HC more often than those not treated with corticosteroids, although this trend did not reach statistical significance (P ¼ 0.064). AdVs were cultured from the urine of 7 of The conditioning regimen was TBI þ CY ± others in 40 patients, TBI þ Mel ± others in 9 patients,TBI þ Bu ± others in 7 patients. Bu þ CY ± others in 3 patients, Bu þ Flu ± others in 3 patients, non-TBI þ non-Bu in 7 patients.
f Parameters for which Po0.2 in the univariate analysis of pre-transplant information were applied to Cox regression model. Statistical significance was defined as Po0.05.
Letter to the Editor 15 patients with late-onset HC and all strains were identified as AdV11. To examine the relationship between viral load and development of late-onset HC in patients undergoing allogeneic HSCT, we performed quantitative PCR for AdV and BK virus (BKV) in all serum and urine samples collected every 1 to 2 weeks after HSCT upto 180 days after HSCT. Primers and probe for identification of all serotypes of AdV and those for identification of BKV were designed, based on the reports described previously. [4] [5] As presented in Figure 1b , the urine AdV loads at the onset of HC in the 7 patients with AdV-HC were markedly higher than the maximum values in the 8 patients with non-AdV-HC or the 54 patients without HC. There was no significant difference in the serum AdV loads among the AdV-HC, non-AdV-HC and no HC group. Lion et al. 6 presented the data that the incidence of AdV viremia in patients with AdV at above 1 Â 10 6 copies/g of stool was significantly higher than in those with AdV levels in stool specimens below this threshold, suggesting that increase of stool AdV load predicts viremia. Accordingly, we investigated the data set for urine and blood. Among seven AdV-HC patients, four patients with AdV viremia (1.1 Â 10 3 to 3.3 Â 10 4 copies/mL) had 1.8 Â 10 5 to 3.3 Â 10 8 copies/mL of urine AdV loads, whereas 3 patients with no AdV viremia had 2.0 Â 10 7 to 2.8 Â 10 8 copies/ mL of urine AdV loads. The cumulative incidence of AdV-HC was substantially different between qualitative PCR and quantitative PCR (Figures 1d-f) . In particular, when AdV at 1.0 Â 10 5 or higher copies/mL was detected in the urine, AdV-HC was diagnosed with 100% sensitivity, 98% specificity, 88% positive predictive value and 100% negative predictive value. On the other hand, qualitative PCR in urine samples displayed 100% sensitivity, 52% specificity, 19% positive predictive value, and 100% negative predictive value. Serial analyses in four of seven patients who developed AdV-HC revealed that adenoviruria reached 41.0 Â 10 4 copies/mL 1-2 weeks before the onset of HC. Accordingly, quantification of the urine AdV load may be more useful for diagnosing AdV-HC than qualitative PCR positivity.
As seven of eight non-AdV-HC patients had significant high urine BKV load between 4.3 Â 10 8 and 1.7 Â 10 10 copies/mL (Figure 1c) , most of the non-AdV-HC was considered to be BKVassociated HC. Among seven AdV-HC patients, three patients had concomitant BKV infections because of over a diagnostic viral load in urine (4.2 Â 10 7 to 7.2 Â 10 9 copies/mL) according to the criteria described by Cesaro et al. 7 The serum BKV load did not influence the development of HC. Therefore, BKV might be an alternative main cause of HC in Japan.
To identify factors predictive of the occurrence of late-onset HC, we first performed univariate analysis of the patients' pretransplant information (Table 1a) . Five factors (age, sex, recipient AdV11 serostatus, type of donor and conditioning regimen with or without Bu) showed Po0.2. Multivariate analysis revealed that recipient AdV11-seropositivity was the only significant risk factor (Table 1b) .
HSCT-related AdV-HC is more frequent in Japan than in other countries (0-4%). 3, 7, 8 Several retrospective Japanese studies have reported risk factors including acute GVHD and chronic GVHD.
1,2,9,10 The influence of seropositivity for AdV was controversial. 1, 2, 9, 10 In this study, we used a neutralizing antibody test to detect anti-AdV11 antibodies because this test is serotype-specific and can detect IgG antibodies for longer period after primary infection than can the complement fixation test. This prospective study revealed that the cumulative incidence of AdV-HC was 64% in the seropositive patients, but only 2% in the seronegative patients (log-rank test, Po0.001). Accordingly, recipient AdV11 serostatus is suggested to be the sole predictor of late-onset HC in Japanese allogeneic HSCT patients. Therefore, patients seropositive for AdV11 may be candidates for prophylactic anti-AdV treatment. It is likely that AdV-HC occurs in approximately 90% of allogeneic HSCT patients when the urine AdV load reached 1.0 Â 10 5 copies/mL or more. Taken together with the finding of the time-course study, preemptive treatment may be recommended to begin when the urine AdV load reaches 1.0 Â 10 4 copies/mL or higher.
